Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
215 hedge funds and large institutions have $3.2B invested in Intercept Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 61 increasing their positions, 73 reducing their positions, and 23 closing their positions.
122% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 23
84% more capital invested
Capital invested by funds: $1.74B → $3.2B (+$1.46B)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
14% more funds holding
Funds holding: 188 → 215 (+27)
16% less call options, than puts
Call options by funds: $264M | Put options by funds: $314M
16% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.3M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$16.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$13.2M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$8.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$44.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$27.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$24M |
| 4 |
Goldman Sachs
New York
|
-$13.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10.2M |
ICPT Hedge Fund Activity: Q4 2019 in Review
215 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2019, worth a combined $3.2B — up 84% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new ICPT positions and 23 closed out — a net gain of 28 holders — while 61 added to existing stakes and 73 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $40.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $44.5M sold.
- 215 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2019, up from 188 in Q3 2019.
- Funds reported $3.2B of Intercept Pharmaceuticals, Inc. stock for Q4 2019, up 84% quarter-over-quarter.
- 51 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2019 and 23 closed out, a net change of +28 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2019 was T. Rowe Price Associates, an estimated $40.8M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q4 2019 was Franklin Resources, an estimated $44.5M sold.
Based on aggregated 13F filings for Q4 2019.